NYSE:AMRX - Amneal Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.40
  • Forecasted Upside: 28.47 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.76
▼ -0.2 (-3.36%)
1 month | 3 months | 12 months
Get New Amneal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.40
▲ +28.47% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Amneal Pharmaceuticals in the last 3 months. The average price target is $7.40, with a high forecast of $9.00 and a low forecast of $5.50. The average price target represents a 28.47% upside from the last price of $5.76.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Amneal Pharmaceuticals. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2021GuggenheimBoost Price TargetBuy$6.50 ➝ $8.00Low
i
3/19/2021Piper SandlerBoost Price TargetOverweight$7.00 ➝ $9.00High
i
3/8/2021The Goldman Sachs GroupUpgradeSell ➝ Buy$4.00 ➝ $6.50High
i
3/1/2021BarclaysBoost Price TargetOverweight$6.00 ➝ $8.00Low
i
12/15/2020SVB LeerinkReiterated RatingHold$5.50High
i
12/14/2020GuggenheimUpgradeNeutral ➝ Buy$5.50Low
i
12/14/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.50 ➝ $6.00Low
i
11/9/2020SVB LeerinkLower Price TargetMarket Perform$6.00 ➝ $5.50Medium
i
10/9/2020Piper SandlerBoost Price TargetOverweight$5.00 ➝ $6.00Medium
i
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$4.00High
i
5/13/2020SunTrust BanksBoost Price TargetBuy$4.00 ➝ $5.00Low
i
5/12/2020SVB LeerinkBoost Price TargetMarket Perform$3.00 ➝ $4.00High
i
5/12/2020GuggenheimUpgradeSell ➝ NeutralHigh
i
4/16/2020Royal Bank of CanadaReiterated RatingHold$4.00Medium
i
4/2/2020Morgan StanleyLower Price TargetEqual Weight$5.00 ➝ $3.00Low
i
2/27/2020SunTrust BanksLower Price TargetBuy$6.00 ➝ $5.00High
i
1/2/2020Royal Bank of CanadaBoost Price TargetSector Perform$3.00 ➝ $4.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
12/13/2019Piper Jaffray CompaniesBoost Price TargetOverweight$4.00 ➝ $7.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
12/12/2019BTIG ResearchBoost Price TargetBuy$5.00 ➝ $7.00High
i
12/12/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
11/12/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
9/12/2019GuggenheimInitiated CoverageSell$2.50High
i
8/6/2019BMO Capital MarketsLower Price TargetMarket Perform$6.00 ➝ $5.00High
i
8/6/2019SunTrust BanksReiterated RatingBuy$5.00High
i
7/22/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$11.00 ➝ $5.00Low
i
Rating by A. Fadia at SVB Leerink LLC
7/11/2019BarclaysSet Price TargetHold$5.00High
i
Rating by Balaji Prasad at Barclays PLC
7/11/2019SunTrust BanksLower Price TargetBuy$16.00 ➝ $9.00High
i
7/11/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $6.00High
i
7/10/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$13.00 ➝ $8.50High
i
7/8/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$11.00Medium
i
6/12/2019Cantor FitzgeraldLower Price TargetOverweight$35.00 ➝ $14.00Low
i
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$9.00High
i
5/21/2019Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$13.00High
i
5/10/2019BMO Capital MarketsLower Price TargetMarket Perform$14.00 ➝ $13.00High
i
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$16.00Low
i
3/8/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$16.00 ➝ $12.00Low
i
Rating by A. Fadia at SVB Leerink LLC
2/28/2019Cantor FitzgeraldReiterated RatingBuy$35.00Low
i
1/3/2019SVB LeerinkReiterated RatingOutperform$25.00 ➝ $19.00High
i
12/14/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $18.00Medium
i
10/16/2018SunTrust BanksDowngradeBuy ➝ Hold$15.00Low
i
10/3/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.00Medium
i
9/4/2018Canaccord GenuityReiterated RatingHold$21.00Medium
i
8/22/2018B. RileyBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.00Low
i
Rating by D. Buck at B. Riley
8/20/2018Canaccord GenuityReiterated RatingHold$21.00Medium
i
8/14/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$18.00 ➝ $21.00High
i
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformHigh
i
8/10/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$19.00 ➝ $20.00Low
i
8/9/2018Cantor FitzgeraldReiterated RatingBuy$35.00Low
i
7/23/2018Morgan StanleyInitiated CoverageOverweight$22.00High
i
6/22/2018B. RileyInitiated CoverageBuy$26.00High
i
Rating by D. Buck at B. Riley
5/18/2018GuggenheimReiterated RatingHoldLow
i
5/18/2018JPMorgan Chase & Co.Initiated CoverageNeutral$18.00Medium
i
(Data available from 6/14/2016 forward)
Amneal Pharmaceuticals logo
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $5.76
$5.75
$6.02

50 Day Range

MA: $5.72
$5.20
$6.44

52 Week Range

Now: $5.76
$3.45
$7.45

Volume

472,001 shs

Average Volume

1,571,444 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Amneal Pharmaceuticals?

The following equities research analysts have issued research reports on Amneal Pharmaceuticals in the last year: Barclays PLC, Guggenheim, Piper Sandler, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for AMRX.

What is the current price target for Amneal Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Amneal Pharmaceuticals in the last year. Their average twelve-month price target is $7.40, suggesting a possible upside of 24.2%. Piper Sandler has the highest price target set, predicting AMRX will reach $9.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $5.50 for Amneal Pharmaceuticals in the next year.
View the latest price targets for AMRX.

What is the current consensus analyst rating for Amneal Pharmaceuticals?

Amneal Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMRX will outperform the market and that investors should add to their positions of Amneal Pharmaceuticals.
View the latest ratings for AMRX.

What other companies compete with Amneal Pharmaceuticals?

How do I contact Amneal Pharmaceuticals' investor relations team?

Amneal Pharmaceuticals' physical mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company's listed phone number is 908-947-3120 and its investor relations email address is [email protected] The official website for Amneal Pharmaceuticals is www.amneal.com.